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Aims. This study assessed whether recent screening recommendations have led to increased diagnosis of type 2 diabetes mellitus
(T2DM) through routine screening. Methods. Respondents to the 2006 US SHIELD survey reported whether a physician told
them they had T2DM, age at diagnosis, specialty of the physician who made the diagnosis, and whether the diagnosis was made
after having symptoms, during routine screening, or when being treated for another health problem. Results. Of 3022 T2DM
respondents, 36% of respondents reported that T2DM diagnosis was made during routine screening alone, 20% after having
symptoms alone, and 6% when being treated for another health problem alone. The proportion of T2DM respondents reporting
a diagnosis based only on screening increased approximately 42% over a 15+-year time span (absolute increase from 31% to 44%)
(P<. 001), whereas symptom-based diagnosis did not change signiﬁcantly (P = .10). T2DM was diagnosed primarily by family
physicians (88.3%). Conclusion. These ﬁndings highlight the importance of regular screening for diabetes and the vital role of
primary care physicians in recognizing individuals with T2DM.
Copyright © 2009 Helena W. Rodbard et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
An estimated 20.6 million adults in the United States have
diabetes mellitus [1]. In patients newly diagnosed with
type 2 diabetes, complications are often present at the
time of diagnosis, suggesting that clinical onset of the
disease occurred years prior to diagnosis [2, 3]. Symptoms
of diabetes often go unrecognized or are assumed to be
insigniﬁcant [4], resulting in a delay of diagnosis.
At present, the American Diabetes Association (ADA)
endorses screening of individuals at high risk for diabetes
but indicates that there is insuﬃcient evidence to support
cost-eﬀective screening of all asymptomatic individuals [5].
The ADA recommends screening be considered at 3-year
intervals beginning at age 45, and in adults with body
mass index (BMI) ≥ 25kg/m2 and who have additional risk
factors (e.g., family history of diabetes, physical inactivity,
certain races/ethnicities, hypertension, dyslipidemia). The
2007 American Association of Clinical Endocrinologists
(AACE) guidelines recommend annual screening for all
individuals 30 years of age and older who are at risk for type
2 diabetes mellitus [6].
In a survey of patients diagnosed with type 2 diabetes in
2003, researchers found that all diagnoses for type 2 diabetes
were either serendipitous, in response to speciﬁc symptoms,
or patient initiated [7]. Clark et al. found that most patients
with a diagnosis of diabetes have little symptomatology or
that the ADA checklist of symptoms associated with diabetes
lacks speciﬁcity for the disease [8]. A study of 504 members
of a medical plan in Minnesota diagnosed with diabetes
between 1995 and 1996 reported that the diagnosis was
made for approximately 50% of the patients at the time
of routine visits (e.g., preventive care visits, chronic disease
visits, preoperative assessments), and that the diagnosis for
43% of patients was made at acute care visits (e.g., visit
for acute respiratory infection, pain, cellulitis) [9]. These2 International Journal of Endocrinology
ﬁndings suggest that symptoms may be the initiating factor
for a small percentage of healthcare visits, and that there
is considerable variability in the care setting in which the
diagnosis of diabetes is made.
The Study to Help Improve Early evaluation and man-
agement of risk factors Leading to Diabetes (SHIELD) is a
longitudinal, observational study of individuals with or at
risk for diabetes. This survey provides an opportunity to
examine the means by which a large group of individuals
with type 2 diabetes mellitus were diagnosed, and to
determine whether there have been changes in patterns of
diagnosis over time. This study describes how individuals
learned they have type 2 diabetes, the specialties of the physi-
cians who made the diagnosis, and the rates of screening for
type 2 diabetes. The purpose of the study was to determine if
diabetesscreeningrateshaveincreasedinrecentyearsamong
individuals with type 2 diabetes mellitus.
2.MaterialsandMethods
The SHIELD study has 3 phases extending over 5 years:
(1) an initial screening phase to identify cases of interest in
the general population; (2) a baseline survey for identiﬁed
cases to collect health status, health knowledge and attitudes,
and current behaviors and treatments; and (3) four annual
surveys to follow disease progression in individuals with an
established diagnosis of diabetes, and the rate of transition
from at risk to a diagnosis of diabetes.
The SHIELD survey methodology has been described in
detail previously [8, 10]. Brieﬂy, the screening survey was
mailed on April 1, 2004, to a stratiﬁed random sample of
200000 US households representative of the US popula-
tion for geographic residence, household size and income,
and age of head of household, identiﬁed by the Taylor
Nelson Sofres National Family Opinion (TNS NFO) panel.
The screening survey was designed to identify individuals
with diabetes and those with cardiometabolic risk factors.
A response rate (computed as completed surveys/surveys
mailed) of 63.7% was obtained from 127420 households
(containing 211097 adults).
The baseline survey was mailed in September and
October 2004 to a representative sample of individuals,
independently sampled (n = 22001), who were identiﬁed
in the screening survey as having type 1 diabetes, type 2
diabetes, or one of 6 risk factors (abdominal obesity, BMI ≥
28kg/m2, reported diagnosis of “cholesterol problems,”
reported diagnosis of high blood pressure/hypertension, and
history of cardiovascular disease). Each respondent group
was balanced to be representative of that population for age,
gender, geographic region, and household size and income
for the US population, and then a random sample from each
group was selected and sent the baseline survey. A response
rate of 71.8% was obtained (n = 15794).
In August 2005, the ﬁrst annual follow-up survey was
mailed to the baseline survey respondents still enrolled in
the TNS NFO panel (n = 19613). The second annual
follow-up survey was mailed in July 2006 to individuals who
had returned either or both the baseline and ﬁrst annual
questionnaires (n = 18445). A 75% response rate was
obtained for the 2006 follow-up survey (n = 13877), with
3022 individuals with type 2 diabetes mellitus.
2.1. Time Since Self-Reported Diagnosis of Type 2 Diabetes
Mellitus. Respondents who self-reported a diagnosis of
type 2 diabetes mellitus were asked to indicate the age
at which they were diagnosed. Time since diagnosis was
computed by subtracting age at diagnosis from current age
and categorized into 3-year increments to capture changes
before and after the ADA screening guidelines published in
2004 [5]. These 3-year increments also coincide with the
ADA recommendation for screening at 3-year intervals. This
resulted in six categories for time since diagnosis: diagnosis
made <3 years, 3 to 5 years, 6 to 8 years, 9 to 11 years, 12
to 14 years, or ≥15 years previously. Age at diagnosis for
type 2 diabetes mellitus was >21 years since type 1 diabetes
respondents were classiﬁed as age at diagnosis of ≤21 years.
Individuals between 22 and 45 years of age were included
because of the recent increase in diabetes diagnosis at
younger ages.
2.2. Method of Diagnosis. Respondents who self-reported a
diagnosis of type 2 diabetes mellitus were asked whether
they were diagnosed because they were tested after having
health symptoms (symptoms), during routine screening/lab
work (screening), or when being treated for another health
problem (other health problem). These categories were used
to determine whether the 2004 ADA screening recommen-
dations [5] have led to a trend toward increased diagnoses
for type 2 diabetes mellitus as a result of routine screening
and decreased diagnoses based on symptoms. Speciﬁcally,
respondents were asked: “How did you ﬁnd out that you
had diabetes? Was it found... (Check all that apply)”
with response categories of “during routine screening/lab
work (blood test, etc.) ordered by my doctor”; “when I
was tested for it after having some health symptoms”; or
“when I was being treated for another health problem.”
Respondents could also check that they were diagnosed
“with home testing” or “other,” but these responses were
considered uninformative for the purposes of this study and
not included in the analysis. Respondents were permitted to
check multiple responses.
Respondents with type 2 diabetes mellitus were also
asked to indicate the specialty of the physician who made
their diagnosis (e.g., family doctor/general practitioner,
endocrinologist, cardiologist, neurologist, or other speciﬁed
physician).
In addition, individuals were asked whether they had a
cardiovascular event, deﬁned as “heart disease/heart attack,
stroke/transient ischemic attack (TIA), or narrow/blocked
arteries/carotid artery disease.” Because a cardiovascular
event may be a trigger for screening and detecting diabetes
mellitus, a subgroup analysis was conducted of individuals
who self-reported a cardiovascular event and who were
given a diagnosis of type 2 diabetes within a year of the
cardiovascular event.International Journal of Endocrinology 3
2.3. Statistical Analysis. Comparisons of the proportion of
individuals reporting a method of diagnosis over time were
made using chi-square tests for trends. Two-sided P values
less than .05 were considered signiﬁcant.
3. Results
There were 3022 respondents with type 2 diabetes mellitus
from the 2006 SHIELD survey, and more than half of these
individuals were female (59.3%), white (85.0%), of non-
Spanish ethnicity (91.6%), and obese (63.4%) (Table 1).
There were 2749 respondents with type 2 diabetes mel-
litus who reported only one method of diagnosis, and
273 respondents who selected 2 or more methods of
diagnosis.
Respondents with type 2 diabetes mellitus reported
that they had had the condition for an average of 10
years (median: 8 years) (Table 1). Approximately 22% of
respondentsreceivedthediagnosisoftype2diabetesmellitus
≥15 years previously, compared with 14% of respondents
who were diagnosed <3y e a r sp r e v i o u s l y( Table 1).
3.1. How Individuals Received the Diagnosis of Type 2
Diabetes Mellitus. For all respondents (including those who
selected multiple methods of diagnosis), 63% of respondents
reported a diagnosis of type 2 diabetes mellitus based on
screening,49%reportedadiagnosisbasedonsymptoms,and
21% reported a diagnosis based on other health problems.
Respondents who selected only one method of diagnosis
were then analyzed to assess diﬀerences over time without
confounding with multiple choices. Analysis of solely the
individuals reporting only one method of diagnosis showed
that 36% of individuals reported a diagnosis of type 2
diabetes mellitus based on screening alone (Table 2). Twenty
percent of individuals reported that the diagnosis was based
on symptoms alone, while 6% of individuals reported that
the diagnosis was based on another health problem alone
(Table 2).
To determine if there was a trend over time in the
method of diagnosis, the proportion of respondents given
the diagnosis by each method was computed for each 3-
year interval since diagnosis. The percentage of individuals
self-reporting the diagnosis of type 2 diabetes mellitus based
on screening alone increased approximately 42% over time,
from 31% in the ≥15 years category to 44% in the <3
years category (P<. 001). In contrast, the percentage
of individuals receiving a diagnosis based on symptoms
alone decreased by 34% and the percentage of individuals
diagnosed when being treated for another health problem
alone increased 14% over time; these changes were not
statistically signiﬁcant (P = .10 for symptoms and P = .59
for other health problem) (Figure 1).
There were 273 (9.0%) respondents with type 2 diabetes
mellitus who reported more than one method of diagnosis
(e.g., they selected both screening and symptoms). Because
respondents could select multiple responses, a separate
analysis was conducted to determine whether the trend
Table 1: Characteristics of SHIELD respondents in 2006 diagnosed
with type 2 diabetes mellitus.
Characteristics
Type 2 diabetes mellitus
n = 3022
Gender, women, % 59.3
Age, years, mean (SD) 61.3 (12.1)
Race
White, % 85.0
Black, % 9.6
Asian or Paciﬁc Islander, % 0.6
Annual household income, %
<$20000 25.4
$20000–$34999 20.4
$35000–$54999 19.9
$55000–$84999 17.4
≥ $85000 16.8
Body mass index (BMI), kg/m2
Underweight or normal weight
(BMI ≤ 24.9), %
9.3
Overweight (BMI 25.0–29.9), % 24.9
Obese (BMI ≥ 30), % 63.4
Cardiometabolic risk factors
Abdominal obesity,§% 83.4
BMI ≥ 28kg/m2,% 77.0
Dyslipidemia diagnosis,§% 82.5
Hypertension diagnosis,§% 75.9
Prior cardiovascular event,§% 41.7
Time since type 2 diabetes
mellitus diagnosis, years
Mean (SD) 10.1 (8.4)
<3 years, % 13.8
3–5 years, % 21.9
6–8 years, % 17.8
9–11 years, % 14.0
12–14 years, % 10.6
≥15 years, % 21.9
§Abdominal obesity: waist circumference for men ≥97cm, for women
≥89cm; dyslipidemia: reported diagnosis of cholesterol problems; hyper-
tension: reported diagnosis of high blood pressure/hypertension; prior
cardiovascular event: reported heart disease/heart attack or stroke/TIA.
in method of diagnosis diﬀered for respondents who self-
reported any combination of responses; however, no diﬀer-
ences emerged.
3.2. Specialty of Physicians Who Made the Diagnosis of Type
2 Diabetes Mellitus. Most individuals with type 2 diabetes
mellitus reported that they received their diagnosis from
their family doctor or general practitioner (88.3%) (Table 3).
Few reported that an endocrinologist (4.4%) had made
the diagnosis, and even fewer reported that a cardiologist
(0.5%) or neurologist (0.7%) had made the diagnosis. This4 International Journal of Endocrinology
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Figure 1: Method of diagnosis for SHIELD individuals with type
2d i a b e t e sm e l l i t u s ,n = 2749∗. ∗Data are shown only for those
respondents who selected only one of three categories: routine
screening, symptoms, or other health problem. P<. 001 for routine
screening change over time, P = .10 for symptoms change over
time, P = .59 for other health problem change over time.
Table 2: Method of diagnosis for type 2 diabetes mellitus among
SHIELD respondents.
Method of diagnosis
All respondents
with type 2
diabetes mellitus
n = 3022
Type 2 diabetes
mellitus selecting
only one method
of diagnosis†
n = 2749
Routine screening, % 63.0 35.5
Testing after
symptoms, % 49.4 20.3
Testing after
treatment for another
health problem, %
20.6 5.6
†percentages do not add to 100% since some respondents chose “other” or
“home testing” as their method of diagnosis.
Table 3: Specialty of physician diagnosing type 2 diabetes mellitus
among SHIELD respondents.
Specialty of physician
making diagnosis of type 2
diabetes mellitus
Type 2 diabetes mellitus
n = 2660
Family doctor/general
practitioner, % 88.3
Endocrinologist, % 4.4
Cardiologist, % 0.5
Neurologist, % 0.7
Other specialist, % 6.0
pattern did not diﬀer signiﬁcantly with respect to duration
of diabetes.
3.3. Cardiovascular Events. There were 826 individuals with
type 2 diabetes mellitus who reported a cardiovascular event
(myocardial infarction, stroke) and age at time of event.
Of these individuals, 141 (17.1%) received the diagnosis of
diabetesmellituswithintheyearfollowingthecardiovascular
event, 23% indicated that the diagnosis was made during
routine screening, 21% reported that it was based on
symptoms, and 13% indicated being diagnosed when being
treated for another health problem.
4. Discussion
The 2004 ADA guidelines recommend screening of indi-
viduals at high risk for diabetes mellitus on a 3-year cycle
starting at age 45 [5]. Early diagnosis of type 2 diabetes
mellitus is a central goal. The SHIELD ﬁndings reveal that
in individuals with type 2 diabetes mellitus, the proportion
of individuals with type 2 diabetes mellitus detected by
screeninghadincreasedfrom2001–2003to2004–2006.Most
of the type 2 diabetes mellitus respondents were obese
and had hypertension and/or dyslipidemia, making them
appropriate candidates for diabetes screening.
These results also indicate that there was no signiﬁcant
change over time in the rate of diagnosis of type 2 diabetes
mellitus due to symptomatic presentation or while being
treated for other health problems. A previous investigation
using SHIELD survey data found that approximately 70%
of respondents did not report having experienced the typical
symptoms of diabetes from the ADA checklist, for example,
frequent urination and increased fatigue [8]. Moreover, only
45% of respondents at high risk for developing diabetes (had
3ormorecardiometabolicriskfactors)reportedoneormore
of the classic symptoms of diabetes, and 55% reported no
symptoms [8]. The presence of one or more of these classic
symptoms alone was generally not suﬃcient impetus for an
individual to consult a physician [8].
The proportion of SHIELD respondents diagnosed on
the basis of another health problem was low (<10%).
Routine physician visits may be an ideal time and setting
to implement screening. A study found that approximately
half of the patients were diagnosed at routine or scheduled
physician visits, and 43% of patients were diagnosed at acute
care visits [9]. In the face of the rapidly increasing incidence
of diabetes mellitus, it is important that physicians identify
individuals at risk for diabetes mellitus during routine
visits and test appropriately. Additionally, other venues for
screening should be explored, such as the new diabetes
screening program for blood donors at the Blood Bank of
Delmarva [11].
A cardiovascular event may serve as a trigger for
screening and detection of type 2 diabetes. It was not
apparent in this study whether patients who experienced
a cardiovascular event were more likely to be screened
for type 2 diabetes. Screening was the most frequently
mentioned self-reported reason for diagnosis in these indi-
viduals. However, we were unable to distinguish those
individualswhowerediagnosedwithtype2diabetesmellitus
speciﬁcally because they had a cardiovascular event from
those in whom the diagnosis was made for other reasons.
We had anticipated that specialists such as cardiologistsInternational Journal of Endocrinology 5
would have been responsible for an increasing percentage of
diagnoses, especially for respondents with a cardiovascular
event. However, our results did not conﬁrm this hypothesis.
Generalists (family doctors/general practitioners) continue
to be the predominant specialty of physician making the
diagnosis of type 2 diabetes.
Limitations of this study include the possible bias
introduced by having only a small percentage (5%–8%)
of households agree to participate in the panel, and the
data tend to underrepresent the very wealthy and very poor
segments of the population, and do not include military
and institutionalized individuals [12, 13]. Respondents who
selected home testing or “other” method of diagnosis (38%)
instead of screening, symptoms or other health problem
for diabetes were not included in the analyses since it
could not be determined if a physician had ever diagnosed
them. The exclusion of these respondents may aﬀect the
generalizability of the study ﬁndings. The SHIELD survey
relied upon self-reporting of clinical data, including the
diagnosis of type 2 diabetes mellitus, method of diagnosis,
age at diagnosis, and the specialty of the physician making
the diagnosis, without independent conﬁrmation by the
physician or examination of medical records. Recall of this
type of information by the respondent could potentially
diﬀer for recently diagnosed respondents compared with
respondents given the diagnosis more than 15 years pre-
viously (median years since diagnosis = 8). Prior analy-
ses have demonstrated generally good correlation between
prevalence of type 2 diabetes mellitus as assessed as self-
report in SHIELD when compared with the prevalence
of diabetes mellitus determined by objectively measured
survey such as the National Health and Nutrition Exami-
nation Survey (NHANES) [10, 14]. Although accuracy and
validity of the self-reported method of diagnosis and age
at diagnosis were not done in this study, other studies
have shown a signiﬁcant correlation and validity of self-
reported data over long recall periods [15–17]. Age at
menopause reported at an interval of almost 20 years showed
signiﬁcant correlation with a mean diﬀerence between ﬁrst-
reported and recalled menopause of 0.5 years [15]. Breast
cancer survivors accurately recalled their treatment and
number of invaded nodes with kappa ≥0.85 [16]. Women
accurately recalled their cause of subfertility after 5.5 years
with kappas of 0.50–0.79 [17]. However, this study does
provide data regarding the method of diagnosis of type
2 diabetes mellitus in a large sample of respondents who
are representative of the US population with a high survey
response rate.
5. Conclusions
This study showed that diagnosis of type 2 diabetes mellitus
by routine screening has increased signiﬁcantly over the
previous 15 years, with the increase occurring in the most
recent years of 2004–2006. However, recognition of typical
symptoms of hyperglycemia and medical testing as part of
careforacuteorotherillnessesrepresentimportantmeansof
detection. These data support the need for more aggressive
screening in order to maximize early detection and the
beneﬁts of early intervention.
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